Dentsply Sirona Appoints New Board Members
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 24 2026
0mins
Should l Buy XRAY?
Source: Newsfilter
- New Board Members: Dentsply Sirona announced the appointments of James D. Forbes and Brian P. McKeon to its Board of Directors, effective February 27, 2026, aimed at enhancing the Board's strategic and financial capabilities to support the company's growth initiatives.
- Extensive Industry Experience: Forbes brings over 30 years of healthcare investment banking experience, having served as Vice Chairman at Morgan Stanley, advising on over $200 billion in financing transactions and over $100 billion in M&A deals, which is expected to provide deep capital allocation and strategic insights for the company.
- Financial Leadership: McKeon has 25 years of experience as a public company CFO, previously serving at IDEXX Laboratories, focusing on strategic choices and capital allocation, which is anticipated to enhance the company's financial management and operational performance.
- Board Refreshment: The appointments are part of the Board's ongoing refreshment process, with Willie Deese retiring and not seeking re-election, reflecting the company's emphasis on leadership during a period of significant transformation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy XRAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on XRAY
Wall Street analysts forecast XRAY stock price to rise
16 Analyst Rating
2 Buy
13 Hold
1 Sell
Hold
Current: 12.680
Low
12.00
Averages
13.04
High
17.00
Current: 12.680
Low
12.00
Averages
13.04
High
17.00
About XRAY
DENTSPLY SIRONA Inc. is a manufacturer of professional dental products and technologies. It develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices. Its Connected Technology Solutions segment includes design, manufacture and sales of its dental technology and equipment products. Its Essential Dental Solutions segment includes the development, manufacture and sales of its value-added endodontic, restorative, and preventive consumable products and small equipment used by dental professionals for the treatment of patients. Its Orthodontic and Implant Solutions segment includes the design, manufacture, and sales of its various digital implant systems and dental implant products, digital dentures and dental professional-directed aligner solutions. Its Wellspect Healthcare segment includes the design, manufacture, and sales of its continence care solutions for urinary and bowel management.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
Dentsply Sirona and Siemens Healthineers Launch Dental MRI System
- FDA Clearance: Dentsply Sirona and Siemens Healthineers' MAGNETOM Free.Max Dental Edition has received FDA clearance, marking a significant validation of the system's potential across multiple dental specialties.
- Clinical Trial Results: The clinical trial demonstrated the system's ability to differentiate active inflammation from healthy and scar tissue, supporting non-invasive assessments of tooth pulp vitality, thereby enhancing diagnostic accuracy and efficiency in dentistry.
- Technological Advantages: The MAGNETOM Free.Max Dental Edition not only visualizes teeth and their positions relative to neighboring teeth and nerves but also provides dentists with a more intuitive observational tool, enhancing clinical decision-making capabilities.
- Market Reaction: Despite the technological breakthrough from FDA clearance, Dentsply Sirona's stock price fell by 1.02% in pre-market trading on Nasdaq, indicating that market reactions to the new product still require further observation.
See More
First Dental-Dedicated MRI System Receives FDA Clearance
- FDA Clearance Milestone: The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona and Siemens Healthineers, has received FDA clearance, marking a significant advancement in dental imaging technology that is expected to enhance diagnostic accuracy and efficiency in dental practices.
- Clinical Trial Findings: The clinical trial validated the system's applicability across multiple dental specialties, including endodontics, periodontics, TMJ, tooth extraction, and orthodontics, showcasing its advantages in non-ionizing imaging that can improve treatment planning.
- Workflow Optimization: With an average workflow time of under 20 minutes, the system significantly streamlines patient preparation, meeting the high-efficiency demands of clinical use and is anticipated to boost operational efficiency in dental clinics.
- Training Opportunity: An advanced two-day training program on ddMRI imaging protocols and clinical procedures will be held at the University of Minnesota in April 2026, equipping clinicians with the necessary skills to effectively utilize this innovative imaging technology.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Dentsply Sirona Reports Mixed Q4 Results with Earnings Miss
- Quarterly Earnings Performance: Dentsply Sirona reported Q4 earnings of $0.27 per share, missing the analyst consensus of $0.28, indicating pressure on profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $961 million, surpassing the analyst estimate of $927 million, suggesting resilience in market demand that could support future growth.
- Cautious Future Outlook: Dentsply Sirona forecasts FY2026 adjusted EPS between $1.40 and $1.50, below market expectations of $1.50, reflecting a cautious stance on future profitability.
- Stock Price Reaction: In pre-market trading, Dentsply Sirona shares fell 2.2% to $14.36, indicating a negative market reaction to the earnings report, which may impact short-term investor sentiment.
See More
Analysis of High-Yield Stocks in Pharma Sector
- Pfizer's Dividend Yield: Pfizer's forward-looking dividend yield has risen to 6.5%, despite its annual revenue declining from over $60 billion in 2022, indicating investor optimism about its upcoming blockbuster drugs, which may attract income-seeking investors.
- Dentsply Sirona's Growth Potential: While Dentsply Sirona's dividend yield is slightly below 5%, its dividend payments have more than doubled over the past decade, showcasing strong dividend growth potential that long-term investors should consider.
- Bristol Myers Squibb's Stability: Bristol Myers Squibb has raised its dividend for 17 consecutive years, and despite its stock price being volatile over the past decade, its profitability remains robust, particularly due to ongoing cash flows from blockbuster drugs like Eliquis and Opdivo.
- Investor Choices: Although Pfizer did not make the Motley Fool's list of top stocks, its undervalued stock price and high dividend yield may present an attractive buying opportunity for investors seeking income in the healthcare sector.
See More
Top High-Yield Healthcare Stocks to Consider
- Pfizer's Current Status: Pfizer (PFE) has seen its annual revenue decline from over $100 billion in 2022 to below $60 billion due to reduced demand for its Comirnaty vaccine and Paxlovid treatment, resulting in its stock price dropping to less than half of its late-2021 peak, currently priced at $26.80 with a market cap of $152 billion and a dividend yield of 6.42%.
- Dentsply Sirona's Growth Potential: Dentsply Sirona (XRAY) offers a dividend yield slightly above 5%, and while it may not increase its annual payout every year, its dividend payments have more than doubled over the past decade, indicating stability and long-term growth potential in the dental supplies market, with a current stock price of $60.59.
- Bristol Myers Squibb's Profitability: Bristol Myers Squibb (BMY) has not seen net growth in its stock price over the past decade, yet it remains profitable with blockbuster drugs like Eliquis and Opdivo, providing steady cash flow, and its dividend yield stands at 4.11%, having been raised for 17 consecutive years, showcasing financial stability.
- Investment Opportunity Analysis: Despite short-term challenges faced by Pfizer and Bristol Myers Squibb, their high dividend yields and potential for new drug developments make these stocks attractive within the healthcare sector, especially during market downturns, allowing investors to capitalize on these undervalued stocks for long-term gains.
See More
Dentsply Sirona and Siemens Healthineers Launch Dental MRI System
- FDA Clearance: Dentsply Sirona and Siemens Healthineers' MAGNETOM Free.Max Dental Edition has received FDA clearance, marking a significant validation of the system's potential across multiple dental specialties.
- Clinical Trial Results: The clinical trial demonstrated the system's ability to differentiate active inflammation from healthy and scar tissue, supporting non-invasive assessments of tooth pulp vitality, thereby enhancing diagnostic accuracy and efficiency in dentistry.
- Technological Advantages: The MAGNETOM Free.Max Dental Edition not only visualizes teeth and their positions relative to neighboring teeth and nerves but also provides dentists with a more intuitive observational tool, enhancing clinical decision-making capabilities.
- Market Reaction: Despite the technological breakthrough from FDA clearance, Dentsply Sirona's stock price fell by 1.02% in pre-market trading on Nasdaq, indicating that market reactions to the new product still require further observation.
See More
First Dental-Dedicated MRI System Receives FDA Clearance
- FDA Clearance Milestone: The MAGNETOM Free.Max Dental Edition, developed by Dentsply Sirona and Siemens Healthineers, has received FDA clearance, marking a significant advancement in dental imaging technology that is expected to enhance diagnostic accuracy and efficiency in dental practices.
- Clinical Trial Findings: The clinical trial validated the system's applicability across multiple dental specialties, including endodontics, periodontics, TMJ, tooth extraction, and orthodontics, showcasing its advantages in non-ionizing imaging that can improve treatment planning.
- Workflow Optimization: With an average workflow time of under 20 minutes, the system significantly streamlines patient preparation, meeting the high-efficiency demands of clinical use and is anticipated to boost operational efficiency in dental clinics.
- Training Opportunity: An advanced two-day training program on ddMRI imaging protocols and clinical procedures will be held at the University of Minnesota in April 2026, equipping clinicians with the necessary skills to effectively utilize this innovative imaging technology.
See More
Dividend Stocks Gain Favor Amid Market Turbulence
- Investor Preference: During turbulent and uncertain market conditions, many investors are turning to dividend-yielding stocks, which typically have high free cash flows and reward shareholders with substantial dividends, indicating a strong desire for stable income.
- Analyst Ratings: Benzinga provides the latest analyst ratings for three high-yielding healthcare stocks, including Perrigo Company PLC, Pfizer Inc, and DENTSPLY SIRONA Inc, assisting investors in making more informed decisions.
- Market Data: Benzinga's analyst ratings page allows traders to sort through ratings based on analyst accuracy, offering a wealth of market data that enhances investor insights into stock performance.
- Attractiveness of Dividend Stocks: High dividend stocks become particularly appealing in uncertain market environments as investors seek to hedge against risks posed by market volatility through stable dividend income.
See More
Dentsply Sirona Reports Mixed Q4 Results with Earnings Miss
- Quarterly Earnings Performance: Dentsply Sirona reported Q4 earnings of $0.27 per share, missing the analyst consensus of $0.28, indicating pressure on profitability that may affect investor confidence.
- Sales Beat Expectations: The company achieved quarterly sales of $961 million, surpassing the analyst estimate of $927 million, suggesting resilience in market demand that could support future growth.
- Cautious Future Outlook: Dentsply Sirona forecasts FY2026 adjusted EPS between $1.40 and $1.50, below market expectations of $1.50, reflecting a cautious stance on future profitability.
- Stock Price Reaction: In pre-market trading, Dentsply Sirona shares fell 2.2% to $14.36, indicating a negative market reaction to the earnings report, which may impact short-term investor sentiment.
See More
